Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children
- 351 Downloads
To assess the cost effectiveness of palivizumab (a preventative treatment against severe respiratory syncytial virus [RSV] infection) in children at high risk of hospitalisation, i.e. preterm infants ≤35 weeks gestation, children with bronchopulmonary dysplasia (BPD) and children with congenital heart disease (CHD).
A decision tree model was developed employing data sources from the published literature, palivizumab clinical trials, official UK price/tariff lists and national population statistics. The comparator was no prophylaxis. The primary perspective of the study was that of the UK NHS. In a societal perspective scenario analysis, the future lost productivity of a child resulting from RSV-related mortality (indirect costs) was also included. The cost of administration of palivizumab, hospital care for RSV infections and the cost of asthma treatment were included.
The analysis was based on a lifetime follow-up period in order to capture the impact of palivizumab on long-term morbidity and mortality resulting from an RSV infection. The primary efficacy outcome in the palivizumab clinical trials was the number of RSV hospitalisations avoided, which was extrapolated to effectiveness outcomes, i.e. number of life-years gained and number of QALYs. Costs and effects were discounted by 3.5%.
In preterm infants and children with BPD, prophylaxis with palivizumab compared with no prophylaxis had an incremental cost-effectiveness ratio (ICER) of £7042/QALY without discounting outcomes, increasing to £16 720/QALY after discounting. In babies with CHD, the use of palivizumab resulted in an ICER of £2427/QALY without discounting outcomes and £6664/QALY after discounting. One-way sensitivity analyses and probabilistic sensitivity analyses confirmed the robustness of the model. A scenario analysis showed that the inclusion of indirect costs leads to further improvement in the cost-effectiveness outcomes for palivizumab.
This study suggests that palivizumab prophylaxis against severe RSV infection in children at high risk may be cost effective from the NHS perspective (vs no prophylaxis), and that the positive clinical and economic benefits may persist beyond one RSV season.
KeywordsCongenital Heart Disease Preterm Infant Respiratory Syncytial Virus Scenario Analysis Respiratory Syncytial Virus Infection
This study was funded by Abbott GmbH &Co. KG, Ludwigshafen, Germany. The authors are grateful to Prof. Adrian Bagust, Economics Division, University of Liverpool, UK, for his support and input in the development of this study. MEDTAP received funding from Abbott GmbH &Co. KG, Ludwigshafen, Germany for the development of the model and writing of the manuscript. Wolfgang Wittenberg is an employee of Abbot GmbH and owns stock in the company. Maximilian Lebmeier was a contractor for Abbott Germany. All the authors contributed significantly to the intellectual content of the paper.
- 1.Hall C. Respiratory syncytial virus. In: Feigin R, Cherry J, editors. Infectious diseases. Philadelphia (PA): W.B. Saunders, 1998Google Scholar
- 3.Canfield S, Simoes E. Prevention of respiratory syncytial virus (RSV) infection: RSV immune globulin intravenous and palivizumab. Ped Ann 1999; 28: 507–514Google Scholar
- 4.Public Health Laboratory Service. Seasonal diseases: winter infections. Respiratory syncytial virus (RSV) infections [online]. Available from URL: http://www.phls.co.uk/seasonal/ rsv/RSV13.htm [Accessed 2005 Jun 15]Google Scholar
- 12.NICE. Guidance for manufacturers and sponsors: technology appraisals No. 5, 2001 [online]. Available from URL: http:// www.nice.org.uk/page.aspx?o 201974 [Accessed 2005 Jun 15]Google Scholar
- 13.Personal Social Services Research Unit. Unit costs of health and social care 2003 [online]. Available from URL: http://www.p ssru.ac.uk/pdf/uc2003/uc2003_inflation.pdf [Accessed 2005 Jun 1]Google Scholar
- 21.Wang EE, Law BJ, Stephens D. Pediatric investigators collaborative network on infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1995; 126: 212–219PubMedCrossRefGoogle Scholar
- 22.Wang E, Tang NK. Immunoglobulin for preventing respiratory syncytial virus infection (Cochrane Review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Chichester (UK): Oxford Update Software, 2004Google Scholar
- 24.National statistics [online]. Available from URL: http:// www.statistics.gov.uk [Accessed 2005 Jun 1]Google Scholar
- 27.Netten A, Curtis L. Unit costs of health and social care 2000. Canterbury, UK: Personal Social Services Research Unit, University of Kent at Canterbury, 2000Google Scholar
- 30.Hospital Episode Statistics 1995–1999. London: Department of Health, 2000 [online]. Available from URL: http:// www.dh.gov.uk/publicationsandstatistics/statistics/hospitalepi sodestatistics/fs/en [Accessed 2005 Jun 15]Google Scholar
- 31.Simoes EAF, Carbonell-Estrany X, Kimpen J, et al. Palavizumab use decreases risk of recurrent wheezing in preterm children. Eur Respir J 2004; 24 Suppl. 48: 212sGoogle Scholar
- 32.International Labour Organization (ILO). Yearbook of Labour Statistics, 1998. Geneva: ILO, 1998Google Scholar
- 33.Organisation for Economic Cooperation and Development (OECD). OECD employment outlook: 2004 edition [online]. Available from URL: http://puck.sourceoecd.org/vl=4300666/ cl=14/nw=1/rpsv/ij/oecdthemes/99980045v2004n8/s1/p11 [Accessed 2006 Dec 1]Google Scholar
- 34.The Chartered Institute of Public Finance and Accountancy. The health service database 2003 (financial year 2002–3). London: CIPFA/HFM, IPF, 2003Google Scholar
- 35.Netten A, Curtis L. Unit costs of health and social care 2003. Canterbury, UK: Personal Social Services Research Unit, University of Kent at Canterbury, 2000Google Scholar
- 39.Rietveld E, Steyerberg E, Polder J, et al. Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis [thesis]. Enschede: Print Partners Ipscamp, 2003: 59–69Google Scholar